Cell death and survival signaling in oncogenesis

Klinische Padiatrie

Volumn 222, Issue 6, 2010, Pages 340-344

  Fulda, S ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Childhood cancer; Oncogenesis; Signaling

Indexed keywords

CASPASE 3; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; INHIBITOR OF APOPTOSIS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BID; PROTEIN KINASE B; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANGIOGENESIS; CARCINOGENESIS; CELL ACTIVATION; CELL DEATH; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; DEREGULATION; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; EPIGENETICS; GENE SILENCING; GLUCOSE METABOLISM; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TUMOR GROWTH; UPREGULATION;

APOPTOSIS; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHILD; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SIGNAL TRANSDUCTION;

EID: 78349247487     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0030-1265169     Document Type: Review

References (66)

1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007 26 1324-1337
2. Adida C, Berrebi D, Peuchmaur M, etal. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998 351 882-883
3. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008 19 325-331
4. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001 11 289-297
5. Barnhart BC, Lee JC, Alappat EC, etal. The death effector domain protein family. Oncogene 2003 22 8634-8644
6. Beltinger C, Bohler T, Karawajew L, etal. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 1998 102 722-728
7. Beltinger C, Kurz E, Bohler T, etal. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998 91 3943-3951 (Pubitemid 28225764)
8. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001 411 355-365
9. Carpten JD, Faber AL, Horn C, etal. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007 448 439-444
10. Chambery D, Mohseni-Zadeh S, de Galle B, etal. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res 1999 59 2898-2902
11. Chen Y, Takita J, Choi YL, etal. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008 455 971-974
12. Cironi L, Riggi N, Provero P, etal. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008 3 e2634
13. Dam V, Morgan BT, Mazanek P, etal. Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 2006 6 177
14. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999 13 2905-2927
15. Debatin KM. Growth control of normal and malignant lymphocytes-cell death research from basic concepts to signal pathways and translation into the clinic. Klin Padiatr 2009 221 332-338
16. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003 22 8543-8567
17. Emi M, Fujiwara Y, Nakajima T, etal. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992 52 5368-5372
18. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001 411 342-348
19. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 1997 11 1833-1841
20. Frühwald MC, Witt O. The epigenetics of cancer in children. Klin Padiatr 2008 220 333-341
21. Fulda S, Los M, Friesen C, etal. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998 76 105-114
22. Fulda S, Kufer MU, Meyer E, etal. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001 20 5865-5877
23. Fulda S, Poremba C, Berwanger B, etal. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 2006 66 10016-10023
24. Fulda S. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anticancer Agents Med Chem 2008 8 533-539
25. Fulda S, Debatin KM. Apoptosis signaling pathways in anticancer therapy. Curr Cancer Ther Rev 2008 4 14-20
26. George RE, Sanda T, Hanna M, etal. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008 455 975-978
27. Gutierrez A, Sanda T, Grebliunaite R, etal. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009 114 647-650
28. Harada K, Toyooka S, Shivapurkar N, etal. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 2002 62 5897-5901 (Pubitemid 35204751)
29. Hartmann W, Kuchler J, Koch A, etal. Activation of phosphatidylinositol- 3-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009 15 4538-4545
30. Hengartner MO. The biochemistry of apoptosis. Nature 2000 407 770-776
31. Ho R, Eggert A, Hishiki T, etal. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002 62 6462-6466
32. Hopkins-Donaldson S, Ziegler A, Kurtz S, etal. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003 10 356-364
33. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007 12 1543-1568
34. Islam A, Kageyama H, Takada N, etal. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000 19 617-623
35. Jaboin J, Kim CJ, Kaplan DR, etal. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3-kinase pathway. Cancer Res 2002 62 6756-6763
36. Janoueix-Lerosey I, Lequin D, Brugieres L, etal. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008 455 967-970
37. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006 94 455-459
38. Kim SY, Toretsky JA, Scher D, etal. The role of IGF-1R in pediatric malignancies. Oncologist 2009 14 83-91
39. Kischkel FC, Hellbardt S, Behrmann I, etal. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 1995 14 5579-5588
40. Kondo Y, Kanzawa T, Sawaya R, etal. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005 5 726-734
41. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007 87 99-163 (Pubitemid 46209992)
42. Kurihara S, Hakuno F, Takahashi S. Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway. Endocr J 2000 47 739-751
43. Li Z, Thiele CJ. Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway. Expert Opin Ther Targets 2007 11 1611-1621
44. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000 21 485-495
45. Micheau O. Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin Ther Targets 2003 7 559-573
46. Miller MA, Karacay B, Zhu X, etal. Caspase 8L, a novel inhibitory isoform of caspase 8, is associated with undifferentiated neuroblastoma. Apoptosis 2006 11 15-24
47. Misawa A, Hosoi H, Arimoto A, etal. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 2000 60 64-69
48. Mohr A, Zwacka RM, Jarmy G, etal. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 2005 24 2421-2429
49. Mosse YP, Laudenslager M, Longo L, etal. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008 455 930-935
50. Munoz J, Lazcoz P, Inda MM, etal. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer 2004 109 673-679
51. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004 4 592-603
52. Osajima-Hakomori Y, Miyake I, Ohira M, etal. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005 167 213-222
53. Oyarzo MP, Medeiros LJ, Atwell C, etal. c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood 2006 107 2544-2547
54. Petak I, Danam RP, Tillman DM, etal. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 2003 10 211-217
55. Pingoud-Meier C, Lang D, Janss AJ, etal. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 2003 9 6401-6409
56. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006 441 424-430
57. Takita J, Yang HW, Chen YY, etal. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 2001 20 4424-4432
58. Tamm I, Richter S, Oltersdorf D, etal. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004 10 3737-3744
59. Teitz T, Wei T, Valentine MB, etal. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000 6 529-535
60. Toretsky JA, Kalebic T, Blakesley V, etal. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997 272 30822-30827 (Pubitemid 27527522)
61. Van Noesel MM, Van Bezouw S, Salomons GS, etal. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002 62 2157-2161
62. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002 2 489-501
63. Weber A, Huesken C, Bergmann E, etal. Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas. Clin Cancer Res 2003 9 5683-5692
64. Wistuba II, Behrens C, Virmani AK, etal. Allelic losses at chromosome 8p2123 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999 59 1973-1979
65. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008 27 5443-5453
66. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994 94 445-448